Orfiril (Sodium Valproate)

Sodium valproate increases the concentration of gamma‑aminobutyric acid (GABA) in the brain, an inhibitory neurotransmitter that reduces neuronal excitability. It also blocks voltage‑gated sodium channels, limiting rapid firing of neurons. These combined actions help control seizures, stabilize mood in bipolar disorder, and prevent migraine attacks by dampening abnormal electrical activity.

The dosage of Orfiril is individualized and determined by the prescribing clinician based on the specific condition, patient age, weight, and response to therapy. Typical dosing regimens for sodium valproate vary widely, and adjustments are made during treatment to achieve optimal therapeutic effect while minimizing adverse reactions. Patients should follow the prescriber’s instructions precisely.

Sodium valproate is classified as Pregnancy Category D, indicating evidence of risk to the fetus, particularly neural‑tube defects, and it should be avoided unless no suitable alternative exists. Use during breastfeeding is also discouraged because the drug is excreted in breast milk and may affect the infant. Consultation with a healthcare provider is essential before use in these situations.

To request Orfiril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including any necessary cold‑chain handling—and assists with import documentation.

Compared with alternatives such as carbamazepine or lamotrigine, sodium valproate offers broad‑spectrum seizure control and is also effective for bipolar disorder and migraine prophylaxis. However, it carries a higher risk of hepatotoxicity, weight gain, and teratogenicity, especially in women of child‑bearing age. Choice of therapy depends on the patient’s clinical profile, comorbidities, and risk tolerance.

Orfiril should be stored at below 25 °C (77 °F) in a dry place, protected from moisture and direct sunlight. Keep the product in its original container and ensure the lid is tightly closed. Do not freeze the tablets, and keep them out of reach of children. Proper storage helps maintain the medication’s stability and potency.

Orfiril is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The tablet should be swallowed whole and not crushed, chewed, or broken unless specifically instructed by a healthcare professional. Consistency in timing and adherence to the prescribed schedule are important for maintaining stable drug levels and therapeutic effect.

The most serious adverse effects of sodium valproate include liver failure, pancreatitis, severe thrombocytopenia, hyperammonemic encephalopathy, and birth defects when used during pregnancy. Patients should be monitored regularly for signs of hepatic dysfunction, abnormal blood counts, and neurological changes. Prompt medical attention is required if any severe symptoms develop.

Orfiril is contraindicated in individuals with known hypersensitivity to sodium valproate or any of its excipients, those with severe hepatic disease, and patients with urea cycle disorders. It should also be avoided in pregnant women unless no alternative therapy is available, and in patients taking certain enzyme‑inducing anticonvulsants that may reduce its efficacy. A healthcare professional should evaluate suitability before prescribing.